Individual InvestorsEmployee Shareholders Institutional InvestorsPrivate Companies Accredited InvestorsSeed & Angel InvestorsAsset Managers & Hedge FundsFamily OfficesVenture Capital FirmsWealth Managers & RIAsWho We Serve Trading Data Liquidity Programs Retirement Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage tool​Browse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunities​Forge PriceA proprietary indicative price, calculated daily, for approximately 200 pre-IPO companiesForge DataAnalyze private markets via Forge’s intuitive web application​Forge Private Market Index​Monitor a benchmark for actively traded private companies ​Forge Accuidity Private Market Index​Invest in an institutionally-managed diversified basket of private companies (QPs only)​Liquidity ProgramsRetain and reward employees with company-sponsored liquidity solutions like tender offers and customized programsSelf-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRAWhat We Do All Insights Private Market Reports Market Insights Buying and Selling Pre-IPO​ All Reports​Private Market UpdatesForge Investment OutlookStartup News and Trends​Private Market Data and Analytics​Tech IPO Calendar for 2025Magnificent 7Private Market Explained​Buying Pre-IPO Shares​Selling Pre-IPO SharesGlossaryVideosFAQsInsights About UsLeadershipInvestor RelationsPeople & CultureCareers About
Log InSign Up
Who We Serve
What We Do
Insights
About
Secondary Marketplace / Trade Private Companies / Buy and Sell 23andMe Stock
23andMe

23andMe Stock

$2.59B
Series F-1 Valuation, Dec 2020
Register To Buy and Sell Private Company Shares
For more details on financing and valuation of private companies, register or login today.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Sign in

23andMe Stock Price

Forge Price 1
Price not available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

23andMe Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
12/23/2020 Series F-1 $385MM $xx.xx $2.59B Glaxosmithkline, Newview Capital, Sequoia Capital
Price per Share
$xx.xx
Shares Outstanding
22,190,201
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Glaxosmithkline, Newview Capital, Sequoia Capital
09/12/2017 Series F $250MM $xx.xx $1.75B Altimeter Capital, Casdin Capital, Euclidean Capital, Fidelity Management, Sequoia Capital, Wallenberg Foundation
Price per Share
$xx.xx
Shares Outstanding
18,006,075
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Altimeter Capital, Casdin Capital, Euclidean Capital, Fidelity Management, Sequoia Capital, Wallenberg Foundation
06/08/2015 Series E $115.25MM $xx.xx $1.1B Casdin Capital, Fidelity Management, Google Ventures, Illumina, Mpm Capital, New Enterprise Associates, Wuxi Venture Fund, Xfund
Price per Share
$xx.xx
Shares Outstanding
10,644,057
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Casdin Capital, Fidelity Management, Google Ventures, Illumina, Mpm Capital, New Enterprise Associates, Wuxi Venture Fund, Xfund
12/10/2012 Series D $58.45MM $xx.xx $288.74MM Google Ventures, Mpm Capital, New Enterprise Associates, Other Individual Investors
Price per Share
$xx.xx
Shares Outstanding
14,435,636
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Google Ventures, Mpm Capital, New Enterprise Associates, Other Individual Investors
11/10/2010 Series C $31.18MM $xx.xx $184.5MM Google Ventures, Johnson & Johnson, Mpm Capital, New Enterprise Associates, Roche Venture Fund
Price per Share
$xx.xx
Shares Outstanding
9,898,011
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Google Ventures, Johnson & Johnson, Mpm Capital, New Enterprise Associates, Roche Venture Fund
12/23/2009 Series B $27.78MM $xx.xx $150.5MM Google, New Enterprise Associates, Other Individual Investors
Price per Share
$xx.xx
Shares Outstanding
9,048,560
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Google, New Enterprise Associates, Other Individual Investors
05/22/2007 Series A $8.95MM $xx.xx $48.5MM Genentech, Google Ventures, Mohr Davidow Ventures, New Enterprise Associates
Price per Share
$xx.xx
Shares Outstanding
7,119,936
Liquidation Pref Order
6
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Genentech, Google Ventures, Mohr Davidow Ventures, New Enterprise Associates
Company Details
23andMe is a consumer genetics and research company looking to help people access, understand, and benefit from the human genome.
Post-Money Valuation 3
$2.59B
Total Funding
$876.61MM
LFR Price per Share
$xx.xx
Last Funding Share Class
Series F-1

23andMe Stock FAQs

To buy and sell 23andMe stock
Can you buy 23andMe stock?
You can no longer buy 23andMe stock on a secondary marketplace. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
How to buy 23andMe stock?
You can no longer buy 23andMe stock on a secondary marketplace. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
Can you sell 23andMe stock?
You can no longer sell stock of 23andMe on Forge. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
How to sell 23andMe stock?
You can no longer sell stock of 23andMe on Forge. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
To learn more about 23andMe stock
Is 23andMe a public company?
23andMe filed for Chapter 11 bankruptcy.
What is 23andMe’s stock price?
There is no stock price available for 23andMe.
What is 23andMe’s stock ticker symbol?
There is no stock ticker symbol for 23andMe.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

23andMe Investors Also Invested in These Private Companies

Glaxosmithkline
Other Individual Investors
Wallenberg Foundation
Wuxi Venture Fund
Genentech

Leadership & Board

Leadership

Steve Schoch
CFO
Kenneth Hillan, M.B., Ch.B
Head of Therapeutics
Anne Wojcicki
CEO & Co-Founder
Fred Kohler
Vice President, People
Kathy Hibbs JD
Chief Legal & Regulatory Officer
Mike Polcari
Vice President & Chief Architect

Board

Patrick Chung
Xfund
Roelof Botha
Sequoia Capital
Anne Wojcicki
23andMe
Neal Mohan
23andMe
Richard Scheller, Ph.D.
Self

23andMe News and Media Highlights

23andMe Study Associates Gene Locus With COVID-19-Related Loss of Smell, Taste

A multi-ancestry genome-wide association study found that genetics likely contributes to the loss of smell or taste in COVID-19 patients.

23andMe to Acquire Telemedicine Platform Company Lemonaid Health for $400M in Cash, Stock

Lemonaid Health, based in San Francisco, offers a platform that provides online access to a variety of telemedicine and pharmacy services.

23andMe Stock Drops on Plan to Buy Health Platform Lemonaid

23andMe shares drop after the consumer genetics company definitively agrees to pay $400 million for health platform Lemonaid.
Browse Insights
Explore Private Companies in the Healthcare providers & services Sector
Sector: Healthcare
Subsector: Healthcare providers & services
Last Funding Round
Company Forge Price Forge Price Change 5 Last Closed Trade Share Class Post-Money Valuation Price per Share Amount Raised
CapsuleCapsule----$xx.xxSeries E$458.12MM$xx.xx$100MM
CarrotCarrot----$xx.xxSeries D$611.49MM$xx.xx$50MM
Collective HealthCollective Health$0.19-5.00%$xx.xxSeries F$1.53B$xx.xx$280MM
DandyDandy----$xx.xxSeries Seed-1$10.41MM$xx.xx$2.63MM
HeartFlowHeartFlow----$xx.xxSeries E$1.65B$xx.xx$305MM
KindbodyKindbody----$xx.xxSeries E-1$420.77MM$xx.xx$79.37MM
Luna Physical TherapyLuna Physical Therapy----$xx.xxSeries B Prime$303.63MM$xx.xx$33.81MM
Mark Cuban Cost Plus Drug CompanyMark Cuban Cost Plus Drug Company----$xx.xx--------
Sword HealthSword Health----$xx.xxSeries E$3B$xx.xx$30MM
Verse MedicalVerse Medical----$xx.xxSeries B-1$288.66MM$xx.xx$40.03MM

Updated on: Mar 25, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.